Intervacc (IVACC) Stock Overview
Develops novel veterinary vaccines for animals in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IVACC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Intervacc AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.21 |
| 52 Week High | SEK 1.46 |
| 52 Week Low | SEK 0.57 |
| Beta | 0.14 |
| 1 Month Change | 8.04% |
| 3 Month Change | 83.61% |
| 1 Year Change | 14.80% |
| 3 Year Change | -75.90% |
| 5 Year Change | -98.46% |
| Change since IPO | -84.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVACC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.3% | -3.8% | -1.4% |
| 1Y | 14.8% | 19.9% | 11.5% |
Return vs Industry: IVACC underperformed the Swedish Biotechs industry which returned 22.4% over the past year.
Return vs Market: IVACC exceeded the Swedish Market which returned 13.4% over the past year.
Price Volatility
| IVACC volatility | |
|---|---|
| IVACC Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: IVACC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IVACC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Carl-Johan Dalsgaard | intervacc.se |
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep.
Intervacc AB (publ) Fundamentals Summary
| IVACC fundamental statistics | |
|---|---|
| Market cap | SEK 412.38m |
| Earnings (TTM) | -SEK 89.37m |
| Revenue (TTM) | SEK 19.07m |
Is IVACC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVACC income statement (TTM) | |
|---|---|
| Revenue | SEK 19.07m |
| Cost of Revenue | SEK 31.70m |
| Gross Profit | -SEK 12.63m |
| Other Expenses | SEK 76.74m |
| Earnings | -SEK 89.37m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -66.22% |
| Net Profit Margin | -468.65% |
| Debt/Equity Ratio | 0.1% |
How did IVACC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 08:06 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intervacc AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Klas Palin | DNB Carnegie Commissioned Research |